Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance
Advanced Science · 2026
DOI: 10.1002/advs.202524150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Zaigang Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Copper, Immunotherapy, Immunity, Innate, Adaptive Immunity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities of the Central South University, Fundamental Research Funds for Central Universities of the Central South University.
Abstract (Originalsprache)
Currently, cluster of differentiation 47 (CD47) and programmed death ligand 1 (PD‐L1) targeted bispecific antibodies have been widely studied in clinical trials to overcome innate and adaptive immune resistance simultaneously. However, the excessive immune‐related adverse events caused by the on‐target off‐tumor immune‐toxicity cast a shadow over their future clinical usage. Thus, how to safely, effectively, and selectively regulate CD47 and PD‐L1 in tumors at the same time is still a difficult issue to solve. Here, we developed a mitochondria‐targeted copper‐withdrawal nanoparticle CYN‐CDA@Alb to more efficaciously depress CD47 and PD‐L1 expression (only 1/50 dosage of common copper chelators), on account of the depression of mitochondria/Adenosine 5’‐monophosphate‐activated protein kinase (AMPK)/c‐MYC signal pathway. By doing this, CYN‐CDA@Alb reverses immune resistance by increasing T cell killing capacity and macrophage phagocytosis ability to tumor cells, leading to the following depressed tumor metastasis and slowed tumor growth. Moreover, CYN‐CDA@Alb also avoids the usually increased innate and adaptive immune resistance after radiotherapy by depressing CD47 and PD‐L1. Our findings altogether suggest the potential usage of copper ion‐depleting nanoparticles as substitutes for CD47/PD‐L1 bispecific antibodies to simultaneously overcome innate and adaptive immune‐resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
ORCID-Profile: Jianliang Shen
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities of the Central South University
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Zhou, Z., Li, K., Li, X., Yi, L., Wang, Z., Ding, H., Wu, S., Liu, F., Li, Y., Cheng, R., & Shen, J. (2026). Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance. Advanced Science. https://doi.org/10.1002/advs.202524150
Vancouver
Zhou Z, Li K, Li X, Yi L, Wang Z, Ding H, et al. Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance. Advanced Science. 2026. doi:10.1002/advs.202524150
BibTeX
@article{Zhou2026,
author = {Zhou, Zaigang and Li, Ke and Li, Xuelan and Yi, Lei and Wang, Zhengxiang and Ding, Huan and Wu, Sheng and Liu, Feiyu and Li, Yuan and Cheng, Rui and Shen, Jianliang},
title = {Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202524150}
}
EUVIMED